Many cancer patients unlikely to survive the disease are often neglected from oncology tests trialing new drugs; the FDA has posted new guidance hoping to boost inclusion of this often omitted group.
The U.S. agency, which has been making moves in this direction over the past few years, said in new, nonbinding guidance that patients with incurable cancers who have had prior drug therapies available on the market should be included for investigational studies of new oncology meds.
